
  
    
      
        Introduction_NNP
        Neutropenic_NNP complications_NNS ,_, defined_VBN as_IN febrile_NN
        neutropenia_NN ,_, severe_JJ neutropenia_NN ,_, or_CC dose_NN delay_NN or_CC reduction_NN
        due_JJ to_TO neutropenia_NN ,_, are_VBP the_DT most_RBS common_JJ side_NN effects_NNS of_IN
        myelosuppressive_JJ chemotherapy_NN [_NN 1_CD 2_CD ]_NN ._. The_DT frequent_JJ
        occurrence_NN of_IN neutropenic_JJ complications_NNS suggests_VBZ that_IN it_PRP is_VBZ
        impossible_JJ to_TO predict_VB accurately_RB which_WDT patients_NNS will_MD
        present_VB with_IN a_DT neutropenic_JJ complication_NN ._. Febrile_NNP
        neutropenia_NN ,_, defined_VBN as_IN an_DT absolute_JJ neutrophil_NN count_NN (_( ANC_NNP )_)
        of_IN more_JJR than_IN 1_CD ._. 0_CD ×_NN 10_CD 9_CD /_NN liter_NN with_IN a_DT temperature_NN of_IN more_JJR
        than_IN 100_CD ._. 6_CD °_NN F_NN ,_, is_VBZ the_DT most_RBS severe_JJ neutropenic_JJ complication_NN
        and_CC can_MD cause_VB prolonged_JJ hospitalization_NN ._. Neutropenic_NNP
        complications_NNS can_MD negatively_RB affect_VB the_DT course_NN of_IN
        chemotherapy_NN ,_, leading_VBG to_TO dose_NN delays_NNS or_CC decreases_NNS to_TO reduce_VB
        a_DT patient_NN 's_POS risk_NN of_IN developing_VBG febrile_NN neutropenia_NN ._. The_DT
        ability_NN to_TO improve_VB predictions_NNS of_IN which_WDT patients_NNS are_VBP at_IN
        risk_NN for_IN neutropenic_JJ complications_NNS might_MD help_VB to_TO reduce_VB the_DT
        morbidity_NN due_JJ to_TO febrile_NN neutropenia_NN and_CC increase_VB the_DT
        likelihood_NN of_IN delivering_VBG full_JJ chemotherapy_NN dose_NN on_IN time_NN ._. In_IN
        addition_NN ,_, hematopoietic_JJ growth_NN factors_NNS could_MD be_VB
        administered_VBN to_TO patients_NNS who_WP need_VBP them_PRP most_JJS ,_, permitting_VBG the_DT
        more_RBR efficient_JJ use_NN of_IN medical_JJ resources_NNS ._.
        Several_JJ publications_NNS have_VBP argued_VBN that_IN the_DT first_JJ
        chemotherapy_NN cycle_NN nadir_NN ANC_NNP is_VBZ a_DT good_JJ predictor_NN of_IN
        neutropenic_JJ complications_NNS in_IN patients_NNS with_IN breast_NN cancer_NN [_NN
        1_CD 2_CD ]_NN ._. These_DT papers_NNS were_VBD based_VBN on_IN retrospective_NN chart_NN
        analyses_NNS and_CC therefore_RB require_VB further_JJ validation_NN in_IN
        additional_JJ chemotherapy_NN regimens_NNS and_CC patient_NN populations_NNS
        before_IN the_DT model_NN can_MD be_VB prospectively_RB implemented_VBN ._.
        Filgrastim_NNP (_( recombinant_JJ methionyl_NN human_JJ granulocyte_NN
        colony-stimulating_JJ factor_NN )_) has_VBZ been_VBN shown_VBN to_TO reduce_VB the_DT
        depth_NN of_IN the_DT nadir_NN ANC_NNP ,_, shorten_VB the_DT duration_NN of_IN
        neutropenia_NN ,_, and_CC reduce_VB the_DT risk_NN of_IN febrile_NN neutropenia_NN [_NN 3_CD
        ]_NN ,_, thereby_RB maintaining_VBG chemotherapy_NN dose_NN [_NN 4_CD 5_CD ]_NN ._. Many_JJ
        patients_NNS with_IN early-stage_JJ breast_NN cancer_NN do_VBP not_RB receive_VB the_DT
        full_JJ chemotherapy_NN dose_NN intensity_NN recommended_VBD in_IN
        conventional_JJ adjuvant_NN chemotherapy_NN regimens_NNS [_NN 6_CD 7_CD 8_CD ]_NN ._.
        Neutropenia_NNP is_VBZ the_DT primary_JJ reason_NN for_IN chemotherapy_NN dose_NN
        delays_NNS and_CC reductions_NNS [_NN 1_CD 6_CD 7_CD ]_NN ._.
        Dose_NNP delay_NN and_CC dose_NN reduction_NN can_MD result_VB in_IN care_NN that_WDT is_VBZ
        less_JJR than_IN optimal_NN ._. Significant_JJ reductions_NNS in_IN total_JJ dose_NN and_CC
        dose_NN intensity_NN have_VBP an_DT adverse_JJ effect_NN on_IN disease-free_JJ
        survival_NN and_CC overall_JJ survival_NN [_NN 9_CD 10_CD ]_NN ._. Because_IN most_JJS dose_NN
        delays_NNS and_CC reductions_NNS occur_VBP after_IN a_DT neutropenic_JJ
        complication_NN or_CC febrile_NN neutropenia_NN ,_, patients_NNS might_MD
        experience_VB an_DT infectious_JJ episode_NN and_CC might_MD need_VB to_TO contend_VB
        with_IN the_DT burden_NN and_CC anxiety_NN associated_VBN with_IN a_DT
        hospitalization_NN and_CC the_DT risk_NN of_IN prolonged_JJ complications_NNS in_IN
        treatment_NN ._. These_DT events_NNS impose_VB potentially_RB preventable_JJ
        burdens_NNS on_IN the_DT patients_NNS ._. The_DT use_NN of_IN hematopoietic_JJ growth_NN
        factors_NNS as_IN primary_JJ prophylaxis_NNS is_VBZ one_CD way_NN of_IN decreasing_VBG the_DT
        burden_NN of_IN neutropenic_JJ complications_NNS ._. However_RB ,_, when_WRB growth_NN
        factors_NNS are_VBP not_RB used_VBN as_IN primary_JJ prophylaxis_NNS ,_, neutropenic_JJ
        complications_NNS serve_VBP as_IN the_DT indicator_NN of_IN the_DT patient_NN 's_POS risk_NN
        for_IN further_JJ neutropenic_JJ complications_NNS ,_, resulting_VBG either_CC in_IN
        growth-factor_JJ treatment_NN as_IN secondary_JJ prophylaxis_NNS or_CC in_IN
        chemotherapy_NN dose_NN delays_NNS or_CC reductions_NNS ._.
        An_DT alternative_JJ treatment_NN strategy_NN can_MD be_VB developed_VBN in_IN
        which_WDT patients_NNS have_VBP a_DT reduced_VBN risk_NN of_IN neutropenic_JJ
        complications_NNS and_CC a_DT higher_JJR likelihood_NN of_IN receiving_VBG a_DT full_JJ
        dose_NN of_IN chemotherapy_NN on_IN time_NN ._. First-cycle_NNP nadir_NN ANC_NNP can_MD be_VB
        used_VBN to_TO identify_VB patients_NNS at_IN risk_NN for_IN neutropenic_JJ
        complications_NNS ._. These_DT patients_NNS could_MD receive_VB prophylactic_JJ
        hematopoietic_JJ growth-factor_JJ support_NN to_TO decrease_VB
        treatment-related_JJ morbidity_NN and_CC to_TO increase_VB the_DT likelihood_NN
        of_IN the_DT administration_NN of_IN full-dose_JJ chemotherapy_NN on_IN
        time_NN ._.
        Silber_NNP and_CC colleagues_NNS [_NN 1_CD ]_NN proposed_VBD a_DT predictive_JJ model_NN
        of_IN neutropenia_NN ,_, dose_NN reduction_NN ,_, or_CC dose_NN delay_NN based_VBN on_IN
        blood_NN counts_VBZ observed_VBN during_IN the_DT first_JJ cycle_NN of_IN
        chemotherapy_NN ._. The_DT model_NN estimates_VBZ the_DT patient_NN 's_POS risk_NN of_IN
        requiring_VBG dose_NN attenuation_NN due_JJ to_TO myelosuppression_NN or_CC ,_,
        alternatively_RB ,_, decreasing_VBG below_IN acceptable_JJ ANC_NNP levels_NNS in_IN
        subsequent_JJ chemotherapy_NN cycles_NNS ._. The_DT model_NN demonstrates_VBZ that_IN
        patients_NNS can_MD be_VB ranked_VBN by_IN probability_NN of_IN presenting_VBG with_IN
        neutropenia_NN in_IN subsequent_JJ cycles_NNS with_IN a_DT high_JJ degree_NN of_IN
        certainty_NN and_CC good_JJ degree_NN of_IN discrimination_NN between_IN
        patients_NNS at_IN high_JJ and_CC low_JJ risk_NN ._. This_DT ranking_VBG permits_VBZ the_DT
        judicious_JJ use_NN of_IN hematopoietic_JJ growth_NN factors_NNS ,_, such_JJ as_IN
        filgrastim_NN ,_, to_TO support_VB patients_NNS who_WP can_MD benefit_VB the_DT most_JJS
        from_IN this_DT treatment_NN ._. Consequently_RB ,_, patients_NNS at_IN high_JJ risk_NN
        for_IN developing_VBG neutropenia_NN will_MD have_VB a_DT greater_JJR chance_NN of_IN
        receiving_VBG full-dose_JJ chemotherapy_NN on_IN time_NN and_CC avoiding_VBG
        febrile_NN neutropenia_NN ._.
        The_DT purpose_NN of_IN our_PRP$ study_NN was_VBD the_DT further_JJ validation_NN of_IN a_DT
        model_NN [_NN 1_CD 11_CD ]_NN that_WDT used_VBD first-cycle_JJ nadir_NN ANC_NNP count_NN to_TO
        predict_VB the_DT risk_NN of_IN febrile_NN neutropenia_NN ,_, dose_NN delay_NN ,_, and_CC
        dose_NN reduction_NN in_IN patients_NNS with_IN breast_NN cancer_NN receiving_VBG
        myelosuppressive_JJ chemotherapy_NN ._. The_DT validation_NN had_VBD two_CD
        parts_NNS :_: a_DT cross-validation_JJ of_IN the_DT original_JJ model_NN with_IN our_PRP$
        data_NNS and_CC a_DT test_NN of_IN the_DT model_NN specification_NN to_TO improve_VB its_PRP$
        predictive_JJ power_NN for_IN our_PRP$ specific_JJ patient_NN population_NN and_CC
        regimen_NN ._.
      
      
        Methods_NNP
        
          Patients_NNS
          The_DT validation_NN sample_NN included_VBD 153_CD chemotherapy-naive_JJ
          patients_NNS with_IN stage_NN I_PRP ,_, II_NNP ,_, IIIa_NNP ,_, or_CC IIIb_NNP breast_NN cancer_NN
          who_WP had_VBD been_VBN treated_VBN with_IN adjuvant_NN chemotherapy_NN during_IN
          1986_CD -_: 92_CD as_IN part_NN of_IN the_DT MD_NNP Anderson_NNP Cancer_NNP Center_NNP (_( MDACC_NNP )_)
          86_CD -_: 12_CD trial_NN ._. Patients_NNS aged_VBN more_JJR than_IN 75_CD years_NNS ,_, those_DT with_IN
          inflammatory_JJ breast_NN cancer_NN ,_, those_DT with_IN a_DT previous_JJ history_NN
          of_IN contralateral_NN breast_NN cancer_NN with_IN higher_JJR stage_NN of_IN
          disease_NN ,_, and_CC those_DT with_IN second_JJ primary_JJ other_JJ than_IN basal_NN
          cell_NN carcinoma_NN of_IN skin_NN or_CC 
          in_IN situ_NN carcinoma_NN of_IN cervix_NN were_VBD
          excluded_VBN from_IN the_DT original_JJ MDACC_NNP 86_CD -_: 12_CD study_NN ._.
          Of_IN the_DT 153_CD patients_NNS participating_VBG in_IN the_DT trial_NN ,_, 10_CD
          were_VBD excluded_VBN from_IN analysis_NN ._. Four_CD patients_NNS had_VBD no_DT
          complete_JJ blood_NN cell_NN count_NN data_NNS recorded_VBN ,_, three_CD had_VBD
          incomplete_JJ chemotherapy_NN delivery_NN information_NN ,_, and_CC three_CD
          had_VBD received_VBN filgrastim_NN ._. Results_NNS are_VBP reported_VBN for_IN the_DT
          remaining_VBG 143_CD patients_NNS ._. Therefore_RB ,_, as_IN in_IN the_DT study_NN by_IN
          Silber_NNP and_CC colleagues_NNS [_NN 1_CD ]_NN ,_, this_DT validation_NN sample_NN
          describes_VBZ the_DT natural_JJ history_NN of_IN neutropenia_NN ._.
        
        
          Treatment_NNP
          Primary_JJ surgical_JJ treatment_NN consisted_VBD of_IN a_DT modified_VBN
          radical_JJ mastectomy_NN or_CC segmental_NN mastectomy_NN ._. If_IN indicated_VBD ,_,
          the_DT patient_NN was_VBD treated_VBN with_IN preoperative_JJ or_CC
          postoperative_JJ local_JJ radiotherapy_NN ._. All_DT patients_NNS were_VBD
          treated_VBN with_IN the_DT FAC_NNP (_( fluorouracil_NN ,_, doxorubicin_NN ,_,
          cyclophosphamide_NN )_) regimen_NN that_WDT consisted_VBD of_IN 50_CD mg_NN /_NN m_NN
          2_CD doxorubicin_NN given_VBN as_IN a_DT continuous_JJ infusion_NN over_IN 72_CD hours_NNS
          starting_VBG on_IN day_NN 1_CD ,_, 500_CD mg_NN /_NN m_NN 2_CD cyclophosphamide_NN
          intravenously_RB on_IN day_NN 1_CD ,_, and_CC 500_CD mg_NN /_NN m_NN 2_CD fluorouracil_NN
          intravenously_RB on_IN days_NNS 1_CD and_CC 4_CD ._. Treatment_NNP was_VBD given_VBN every_DT
          3_CD or_CC 4_CD weeks_NNS for_IN a_DT total_NN of_IN six_CD cycles_NNS ._. Complete_JJ blood_NN
          counts_VBZ with_IN differential_NN counts_NNS were_VBD usually_RB obtained_VBN on_IN
          days_NNS 1_CD ,_, 8_CD ,_, and_CC 15_CD of_IN each_DT cycle_NN ._. Chemotherapy_NNP was_VBD usually_RB
          delayed_VBN if_IN the_DT ANC_NNP was_VBD less_JJR than_IN 1_CD ._. 5_CD ×_NN 10_CD 9_CD /_NN liter_NN on_IN the_DT
          planned_VBN first_JJ day_NN of_IN the_DT cycle_NN ._. Dose_NNP delays_NNS were_VBD usually_RB
          for_IN 1_CD week_NN ._. The_DT chemotherapy_NN dose_NN was_VBD reduced_VBN if_IN ,_, on_IN the_DT
          previous_JJ cycle_NN ,_, the_DT nadir_NN ANC_NNP was_VBD less_JJR than_IN 0_CD ._. 5_CD ×_NN 10_CD
          9_CD /_NN liter_NN or_CC if_IN the_DT patient_NN experienced_VBD an_DT episode_NN of_IN
          febrile_NN neutropenia_NN ,_, defined_VBN as_IN an_DT ANC_NNP of_IN less_JJR than_IN 1_CD ._. 0_CD ×_NN
          10_CD 9_CD /_NN liter_NN with_IN a_DT temperature_NN of_IN more_JJR than_IN 100_CD ._. 6_CD °_NN F_NN ._. Dose_NNP
          reductions_NNS usually_RB consisted_VBD of_IN a_DT 20_CD %_NN reduction_NN in_IN dosage_NN
          of_IN all_DT chemotherapy_NN drugs_NNS ._.
        
        
          Outcome_NNP definition_NN
          A_DT neutropenia-related_JJ event_NN was_VBD defined_VBN similarly_RB to_TO
          that_DT in_IN the_DT study_NN by_IN Silber_NNP and_CC colleagues_NNS [_NN 1_CD ]_NN :_: a_DT
          nadir_NN ANC_NNP of_IN 0_CD ._. 5_CD ×_NN 10_CD 9_CD /_NN liter_NN or_CC less_JJR ,_, a_DT
          neutropenia-related_JJ dose_NN reduction_NN of_IN 15_CD %_NN or_CC more_JJR of_IN the_DT
          planned_VBN dose_NN of_IN any_DT agent_NN ,_, a_DT neutropenia-related_JJ dose_NN
          delay_NN of_IN 7_CD days_NNS or_CC more_JJR ,_, or_CC a_DT febrile-neutropenic_JJ
          episode_NN ._. Delays_NNP and_CC reductions_NNS were_VBD related_VBN to_TO
          neutropenia_NN ,_, and_CC the_DT reasons_NNS for_IN the_DT dose_NN modifications_NNS
          were_VBD documented_VBN ._. A_DT response_NN group_NN for_IN the_DT risk_NN model_NN
          consists_VBZ of_IN all_DT patients_NNS who_WP experienced_VBD at_IN least_JJS one_CD
          neutropenia-related_JJ event_NN after_IN the_DT first_JJ cycle_NN of_IN
          chemotherapy_NN ._. The_DT ANC_NNP cutoff_NN point_NN to_TO define_VB an_DT event_NN was_VBD
          0_CD ._. 5_CD ×_NN 10_CD 9_CD /_NN liter_NN ,_, rather_RB than_IN 0_CD ._. 25_CD ×_NN 10_CD 9_CD /_NN liter_NN used_VBN in_IN
          the_DT Silber_NNP model_NN to_TO accommodate_VB the_DT physician_NN practice_NN
          style_NN associated_VBN with_IN patients_NNS in_IN the_DT validation_NN
          sample_NN ._.
        
        
          Statistical_NNP methods_NNS
          The_DT originally_RB estimated_VBN Silber_NNP risk_NN model_NN was_VBD
          cross-validated_JJ with_IN the_DT MDACC_NNP sample_NN ._. We_PRP used_VBD the_DT same_JJ
          definitions_NNS as_IN in_IN the_DT original_JJ model_NN for_IN the_DT predictor_NN
          variables_NNS ._. The_DT distribution_NN of_IN these_DT predictor_NN variables_NNS
          was_VBD compared_VBN across_IN the_DT original_JJ Silber_NNP and_CC validation_NN
          MDACC_NNP study_NN samples_NNS ._. The_DT outcome_NN variable_JJ in_IN the_DT
          validation_NN sample_NN differs_VBZ in_IN that_IN an_DT ANC_NNP cutoff_NN point_NN of_IN
          0_CD ._. 5_CD ×_NN 10_CD 9_CD /_NN liter_NN is_VBZ used_VBN in_IN the_DT compound_NN outcome_NN
          definition_NN ._. Given_VBN this_DT difference_NN in_IN ANC_NNP cutoff_NN point_NN and_CC
          the_DT difference_NN in_IN chemotherapy_NN regimens_NNS used_VBN in_IN the_DT two_CD
          samples_NNS ,_, the_DT absolute_JJ predicted_VBD probabilities_NNS of_IN events_NNS
          resulting_VBG from_IN the_DT cross-validation_JJ might_MD not_RB be_VB
          interpretable_JJ ,_, but_CC their_PRP$ relative_JJ magnitude_NN (_( or_CC ranking_NN
          of_IN patients_NNS by_IN predicted_VBD probability_NN of_IN an_DT event_NN )_) is_VBZ
          valid_JJ ._. To_TO assess_VB the_DT cross-validation_JJ results_NNS ,_, we_PRP divided_VBD
          the_DT patients_NNS into_IN predicted_VBD positive_JJ and_CC predicted_VBD
          negative_JJ groups_NNS by_IN using_VBG varying_VBG probability_NN cut_NN points_NNS ._.
          This_DT process_NN is_VBZ equivalent_JJ to_TO ranking_VBG the_DT patients_NNS by_IN
          their_PRP$ predicted_VBD event_NN probability_NN and_CC dividing_VBG the_DT ranked_VBN
          list_NN in_IN all_DT possible_JJ ways_NNS ,_, declaring_VBG the_DT higher-ranked_JJ
          patients_NNS predicted_VBD positive_JJ and_CC the_DT lower-ranked_JJ patients_NNS
          predicted_VBD negative_JJ ._.
          The_DT sensitivity_NN and_CC specificity_NN of_IN each_DT possible_JJ
          resulting_VBG classification_NN are_VBP summarized_VBD in_IN a_DT
          receiver-operating-characteristic_JJ curve_NN plot_NN ._. The_DT 
          C_NNP -_: statistic_NN (_( area_NN under_IN the_DT
          receiver-operating-characteristic_JJ curve_NN )_) [_NN 12_CD ]_NN ,_, which_WDT
          summarized_VBD the_DT sensitivity_NN and_CC specificity_NN across_IN the_DT
          entire_JJ (_( 0_CD to_TO 1_LS )_) range_NN of_IN probability_NN cut_NN points_NNS ,_, is_VBZ
          reported_VBN together_RB with_IN the_DT sensitivity_NN and_CC specificity_NN
          rates_NNS for_IN the_DT optimal_NN classification_NN table_NN ._. This_DT
          validation_NN process_NN does_VBZ not_RB address_VB the_DT effect_NN of_IN
          concurrent_JJ radiotherapy_NN because_IN none_NN of_IN the_DT patients_NNS in_IN
          the_DT validation_NN sample_NN were_VBD treated_VBN with_IN this_DT modality_NN ._. As_IN
          a_DT result_NN ,_, the_DT indicator_NN variable_JJ for_IN concurrent_JJ
          radiotherapy_NN present_JJ in_IN the_DT original_JJ model_NN is_VBZ set_VBN to_TO 0_CD ,_,
          effectively_RB applying_VBG the_DT model_NN to_TO patients_NNS with_IN no_DT
          concurrent_JJ radiotherapy_NN ._.
          For_IN the_DT model-specification_JJ test_NN ,_, the_DT same_JJ variables_NNS
          used_VBN to_TO predict_VB neutropenic_JJ complications_NNS in_IN the_DT Silber_NNP
          model_NN were_VBD fitted_JJ with_IN a_DT logistic_JJ regression_NN to_TO our_PRP$ data_NNS
          and_CC the_DT significance_NN was_VBD reported_VBN ._. Furthermore_RB ,_, we_PRP
          explored_JJ other_JJ potential_JJ predictors_NNS to_TO examine_VB whether_IN
          new_JJ significant_JJ risk_NN factors_NNS would_MD emerge_VB ._. The_DT
          discrimination_NN and_CC calibration_NN of_IN the_DT model_NN fitted_JJ to_TO our_PRP$
          data_NNS and_CC original_JJ models_NNS were_VBD compared_VBN by_IN using_VBG the_DT 
          C_NNP -_: statistic_NN and_CC the_DT
          Hosmer-_NNP Lemeshow_NNP statistic_NN [_NN 13_CD ]_NN ._. The_DT
          receiver-operating-characteristic_JJ curves_NNS for_IN the_DT two_CD
          models_NNS were_VBD plotted_VBD and_CC compared_VBN ._. The_DT magnitudes_NNS of_IN the_DT
          risk_NN factors_NNS '_POS effects_NNS were_VBD compared_VBN across_IN the_DT validation_NN
          and_CC original_JJ models_NNS ._. Regression_NNP coefficient_NN differences_NNS
          were_VBD tested_VBN with_IN an_DT asymptotic_JJ normal_JJ test_NN and_CC the_DT
          estimated_VBN probability_NN of_IN event_NN curves_NNS derived_VBN from_IN the_DT
          original_NN and_CC validation_NN models_NNS were_VBD plotted_VBD for_IN
          comparison_NN ._. Finally_RB ,_, we_PRP assessed_VBD the_DT importance_NN of_IN
          first-cycle_JJ nadir_NN ANC_NNP as_IN a_DT predictor_NN of_IN subsequent_JJ
          episodes_NNS of_IN febrile_NN neutropenia_NN and_CC of_IN reduced_VBN dose_NN
          intensity_NN (_( not_RB more_JJR than_IN 85_CD %_NN of_IN planned_VBN dose_NN intensity_NN )_)
          by_IN comparing_VBG the_DT proportion_NN of_IN observed_VBD events_NNS in_IN
          patients_NNS grouped_VBN by_IN first-cycle_JJ nadir_NN ANC_NNP ranges_NNS ._.
          Statistical_NNP analyses_NNS were_VBD performed_VBN by_IN using_VBG SAS_NNP 8_CD ._. 00_CD for_IN
          Windows_NNP (_( SAS_NNP Institute_NNP Inc_NNP ,_, Cary_NNP ,_, NC_NNP )_) ._. All_DT reported_VBN 
          P_NN values_NNS are_VBP two-sided_JJ ._.
        
      
      
        Results_NNS
        
          Patients_NNS
          Patient_NNP characteristics_NNS in_IN the_DT validation_NN sample_NN were_VBD
          similar_JJ to_TO those_DT described_VBD in_IN the_DT Silber_NNP model_NN [_NN 1_CD ]_NN ,_,
          except_IN for_IN the_DT distribution_NN of_IN patients_NNS with_IN positive_JJ
          nodes_NNS (_( Table_NNP 1_LS )_) ._. In_IN Silber_NNP 's_POS patient_NN sample_NN ,_, one-third_NN of_IN
          the_DT patients_NNS were_VBD treated_VBN with_IN the_DT less_RBR myelosuppressive_JJ
          CMF_NNP (_( cyclophosphamide_NN ,_, methotrexate_NN ,_, fluorouracil_NN )_)
          chemotherapy_NN regimen_NN ,_, and_CC the_DT CAF_NNP (_( cyclophosphamide_NN ,_,
          doxorubicin_NN ,_, fluorouracil_NN )_) regimen_NN consisted_VBD of_IN 30_CD mg_NN /_NN m_NN
          2_CD compared_VBN with_IN the_DT 50_CD mg_NN /_NN m_NN 2_CD CAF_NNP regimen_NN used_VBN in_IN our_PRP$
          validation_NN sample_NN ._. The_DT rate_NN of_IN neutropenic_JJ events_NNS was_VBD
          markedly_RB higher_JJR among_IN the_DT validation_NN patients_NNS than_IN in_IN
          patients_NNS in_IN the_DT Silber_NNP study_NN (_( 84_CD %_NN versus_CC 47_CD %_NN )_) ._.
        
        
          Outcome_NNP definition_NN
          The_DT cross-validation_JJ of_IN the_DT Silber_NNP logistic_JJ regression_NN
          model_NN applied_VBN to_TO our_PRP$ data_NNS produced_VBD a_DT 
          C_NNP -_: statistic_NN of_IN 0_CD ._. 78_CD ._. The_DT
          receiver-operating-characteristic_JJ curve_NN for_IN this_DT analysis_NN
          (_( Fig_NNP ._. 1_LS )_) can_MD be_VB compared_VBN with_IN the_DT
          receiver-operating-characteristic_JJ curve_NN from_IN the_DT original_JJ
          Silber_NNP model_NN and_CC an_DT MDACC_NNP data-fitted_JJ model_NN ._. The_DT
          predictions_NNS obtained_VBN from_IN the_DT model_NN for_IN this_DT independent_JJ
          set_NN of_IN patients_NNS confirm_VBP the_DT validity_NN of_IN the_DT Silber_NNP model_NN ._.
          As_IN occurs_VBZ typically_RB ,_, the_DT predictive_JJ power_NN is_VBZ not_RB as_IN high_JJ
          in_IN a_DT cross-validation_JJ as_IN in_IN the_DT original_JJ model_NN
          development_NN (_( 
          C_NNP =_SYM 0_CD ._. 83_CD in_IN the_DT Silber_NNP model_NN )_) ,_, but_CC
          the_DT cross-validation_JJ 
          C_NNP -_: statistic_NN is_VBZ strong_JJ evidence_NN for_IN
          the_DT usefulness_NN of_IN the_DT model_NN ._. The_DT cross-validation_JJ optimal_NN
          sensitivity_NN and_CC specificity_NN rates_NNS (_( obtained_VBN for_IN a_DT cutoff_NN
          probability_NN of_IN 0_CD ._. 45_CD )_) were_VBD 66_CD ._. 6_CD %_NN and_CC 73_CD ._. 3_LS %_NN ,_,
          respectively_RB ._.
          The_DT model_NN fitted_JJ to_TO the_DT MDACC_NNP data_NN (_( Table_NNP 2_LS )_) confirms_VBZ
          the_DT significance_NN of_IN the_DT first-cycle_JJ nadir_NN ANC_NNP effect_NN (_( 
          P_NN <_NN 0_CD ._. 0001_CD )_) ._. It_PRP was_VBD the_DT only_RB
          significant_JJ predictor_NN of_IN subsequent_JJ neutropenic_JJ events_NNS
          among_IN those_DT available_JJ in_IN the_DT validation_NN sample_NN ,_, including_VBG
          age_NN ,_, menopausal_NN status_NN ,_, receptor_NN status_NN ,_, previous_JJ
          radiotherapy_NN ,_, and_CC first-cycle_JJ hemoglobin_NN decrease_NN ._. The_DT
          decrease_NN in_IN hemoglobin_NN concentration_NN from_IN baseline_NN to_TO
          first-cycle_JJ nadir_NN was_VBD only_RB borderline_NN significant_JJ (_( 
          P_NN =_SYM 0_CD ._. 0686_CD )_) ._. These_DT results_NNS suggest_VBP
          that_IN the_DT first-cycle_JJ nadir_NN ANC_NNP is_VBZ an_DT excellent_JJ predictor_NN
          of_IN neutropenic_JJ events_NNS in_IN subsequent_JJ cycles_NNS ._. Model_NNP
          discrimination_NN ,_, as_IN measured_VBN by_IN the_DT 
          C_NNP -_: statistic_NN (_( or_CC the_DT area_NN under_IN the_DT
          receiver-operating-characteristic_JJ curve_NN )_) ,_, was_VBD similar_JJ in_IN
          the_DT original_JJ Silber_NNP and_CC validation_NN studies_NNS (_( 0_CD ._. 83_CD versus_CC
          0_CD ._. 78_CD )_) ._. Figure_NN 1_CD compares_VBZ the_DT
          receiver-operating-characteristic_JJ curves_NNS for_IN the_DT Silber_NNP
          and_CC validation_NN models_NNS ._. As_IN with_IN the_DT Silber_NNP model_NN ,_, the_DT
          validation_NN model_NN was_VBD well_RB calibrated_VBN throughout_IN the_DT
          entire_JJ range_NN of_IN probabilities_NNS ,_, as_IN assessed_VBN by_IN the_DT
          nonsignificant_NN Hosmer-_NNP Lemeshow_NNP statistic_NN ._.
          The_DT MDACC_NNP model_NN also_RB confirms_VBZ the_DT magnitude_NN of_IN the_DT
          effect_NN ._. The_DT estimated_VBN odds_NNS ratio_NN of_IN 4_CD ._. 8_CD for_IN a_DT unit_NN (_( 1_CD ._. 0_CD ×_NN
          10_CD 9_CD /_NN liter_NN )_) decrease_VB in_IN first-cycle_JJ nadir_NN ANC_NNP is_VBZ not_RB
          significantly_RB different_JJ from_IN 4_CD ._. 4_CD in_IN the_DT Silber_NNP study_NN ._. An_DT
          asymptotic_JJ 
          z_SYM -_: test_NN for_IN the_DT comparison_NN of_IN the_DT
          estimated_VBN regression_NN coefficients_NNS has_VBZ a_DT 
          P_NN value_NN of_IN 0_CD ._. 91_CD ._. Estimates_NNS of_IN
          first-cycle_JJ hemoglobin_NN decrease_NN effects_NNS were_VBD almost_RB
          identical_JJ across_IN models_NNS ._.
          Model-derived_NNP point_NN estimates_NNS for_IN the_DT probability_NN of_IN
          subsequent_JJ neutropenic_JJ events_NNS as_IN a_DT function_NN of_IN
          first-cycle_JJ nadir_NN ANC_NNP and_CC an_DT average_JJ first-cycle_JJ decrease_NN
          in_IN hemoglobin_NN concentration_NN are_VBP presented_VBN in_IN Fig_NNP ._. 2_LS ._. The_DT
          higher_JJR level_NN of_IN the_DT estimated_VBN probability_NN curve_NN for_IN the_DT
          MDACC_NNP sample_NN might_MD be_VB due_JJ to_TO the_DT higher_JJR myelotoxicity_NN of_IN
          the_DT CAF_NNP regimen_NN used_VBN in_IN the_DT validation_NN sample_NN ._. The_DT
          observed_VBD proportions_NNS of_IN patients_NNS who_WP experienced_VBD febrile_NN
          neutropenia_NN and_CC received_VBD 85_CD %_NN or_CC less_JJR of_IN the_DT planned_VBN dose_NN
          intensity_NN in_IN the_DT MDACC_NNP study_NN are_VBP presented_VBN in_IN Figs_NNP 3_CD and_CC
          4_CD by_IN first-cycle_JJ nadir_NN ANC_NNP ._. The_DT association_NN of_IN the_DT ANC_NNP at_IN
          first-cycle_JJ nadir_NN with_IN each_DT of_IN the_DT outcomes_NNS is_VBZ evident_JJ ._. A_DT
          significantly_RB higher_JJR percentage_NN of_IN patients_NNS with_IN a_DT
          first-cycle_JJ nadir_NN ANC_NNP of_IN 0_CD ._. 25_CD ×_NN 10_CD 9_CD /_NN liter_NN or_CC less_RBR
          experienced_JJ febrile_NN neutropenia_NN (_( 30_CD %_NN versus_CC 10_CD %_NN ,_, 
          P_NN =_SYM 0_CD ._. 04_CD )_) and_CC received_VBD 85_CD %_NN or_CC less_JJR
          of_IN the_DT planned_VBN dose_NN intensity_NN (_( 55_CD %_NN versus_CC 32_CD %_NN ,_, 
          P_NN =_SYM 0_CD ._. 05_CD )_) ._.
        
      
      
        Discussion_NNP
        Several_JJ retrospective_NN analyses_NNS [_NN 1_CD 2_CD ]_NN using_VBG a_DT variety_NN
        of_IN chemotherapies_NNS have_VBP consistently_RB resulted_VBN in_IN first-cycle_JJ
        nadir_NN ANC_NNP as_IN a_DT primary_JJ predictor_NN of_IN neutropenia-related_JJ
        events_NNS in_IN patients_NNS with_IN breast_NN cancer_NN ._. Here_RB we_PRP confirm_VBP the_DT
        results_NNS obtained_VBN in_IN the_DT previous_JJ analyses_NNS by_IN Silber_NNP and_CC
        colleagues_NNS [_NN 1_CD ]_NN ,_, which_WDT is_VBZ important_JJ because_IN the_DT data_NNS used_VBN
        in_IN this_DT study_NN come_VB from_IN a_DT prospective_JJ clinical_JJ trial_NN ,_,
        whereas_IN the_DT other_JJ data_NN sets_NNS were_VBD collected_VBN from_IN patient_NN
        charts_NNS in_IN an_DT uncontrolled_JJ environment_NN ._. The_DT data_NNS in_IN this_DT
        study_NN represent_VBP a_DT homogenous_JJ population_NN receiving_VBG
        standardized_JJ chemotherapy_NN ,_, and_CC the_DT collection_NN procedures_NNS
        ensure_VBP high-quality_JJ data_NNS ._. The_DT cross-validation_JJ analysis_NN
        showed_VBD that_IN the_DT original_JJ predictive_JJ model_NN successfully_RB
        classified_VBD patients_NNS by_IN their_PRP$ risk_NN of_IN neutropenic_JJ event_NN ._. The_DT
        model_NN fitted_JJ to_TO the_DT validation_NN data_NN results_NNS in_IN the_DT same_JJ
        specification_NN and_CC similar_JJ variable_JJ coefficient_NN magnitudes_NNS
        to_TO those_DT in_IN the_DT original_JJ model_NN ._.
        Our_PRP$ model_NN differs_VBZ somewhat_RB from_IN the_DT Silber_NNP model_NN ._. First_LS ,_,
        the_DT impact_NN of_IN the_DT change_NN in_IN hemoglobin_NN concentration_NN is_VBZ
        significant_JJ in_IN the_DT Silber_NNP model_NN and_CC not_RB significant_JJ in_IN this_DT
        data_NNS set_VBN ,_, although_IN the_DT magnitude_NN of_IN the_DT effect_NN is_VBZ similar_JJ
        in_IN both_DT models_NNS ._. We_PRP do_VBP not_RB believe_VB that_IN hemoglobin_NN
        concentrations_NNS have_VBP a_DT direct_JJ impact_NN on_IN neutropenic_JJ
        complications_NNS ;_: however_RB ,_, low_JJ hemoglobin_NN concentrations_NNS
        probably_RB provide_VBP further_JJ indication_NN of_IN bone_NN marrow_NN
        depletion_NN ._. It_PRP is_VBZ possible_JJ that_IN the_DT impact_NN of_IN change_NN in_IN
        hemoglobin_NN concentration_NN in_IN the_DT models_NNS will_MD vary_VB by_IN
        chemotherapy_NN regimen_NN ._.
        On_IN the_DT basis_NN of_IN the_DT cumulated_JJ published_VBN evidence_NN ,_, the_DT
        model_NN seems_VBZ to_TO be_VB robust_JJ ._. The_DT model_NN was_VBD tested_VBN in_IN several_JJ
        chemotherapy_NN regimens_NNS and_CC in_IN various_JJ clinical_JJ environments_NNS ._.
        It_PRP seems_VBZ that_IN the_DT model_NN 's_POS specification_NN and_CC the_DT magnitude_NN
        of_IN the_DT coefficient_NN 's_POS effect_NN is_VBZ consistent_JJ across_IN
        chemotherapy_NN regimens_NNS ._. The_DT inclination_NN is_VBZ to_TO consider_VB the_DT
        implementation_NN of_IN this_DT model_NN prospectively_RB ._. Before_IN such_JJ a_DT
        step_NN is_VBZ undertaken_VBN ,_, some_DT issues_NNS need_VBP to_TO be_VB discussed_VBN to_TO
        improve_VB our_PRP$ understanding_NN of_IN the_DT model_NN 's_POS limitation_NN and_CC its_PRP$
        usefulness_NN ._.
        The_DT major_JJ challenge_NN to_TO the_DT model_NN 's_POS prospective_JJ
        implementation_NN is_VBZ the_DT uncertainty_NN that_IN a_DT greater_JJR dose_NN
        intensity_NN would_MD result_VB in_IN clinical_JJ benefit_NN ,_, such_JJ as_IN
        survival_NN ._. Although_IN it_PRP is_VBZ not_RB within_IN the_DT scope_NN of_IN this_DT study_NN
        to_TO answer_VB this_DT important_JJ question_NN ,_, it_PRP should_MD be_VB emphasized_VBN
        that_IN the_DT model_NN provides_VBZ some_DT other_JJ distinctive_JJ and_CC
        practical_JJ benefits_NNS ._. Successful_JJ application_NN of_IN the_DT model_NN
        will_MD clearly_RB define_VB the_DT patient_NN group_NN that_WDT should_MD not_RB
        receive_VB growth-factor_JJ support_NN and_CC who_WP can_MD receive_VB the_DT full_JJ
        dose_NN on_IN time_NN without_IN a_DT risk_NN of_IN complications_NNS ._. The_DT ability_NN
        to_TO define_VB the_DT population_NN that_WDT does_VBZ not_RB require_VB growth_NN
        factors_NNS on_IN the_DT basis_NN of_IN a_DT quantitative_JJ clinical_JJ indicator_NN
        has_VBZ an_DT immediate_JJ benefit_NN to_TO the_DT patients_NNS and_CC the_DT health_NN
        care_NN system_NN :_: it_PRP diverts_NNS resources_NNS from_IN patients_NNS who_WP will_MD
        not_RB benefit_VB to_TO those_DT who_WP will_MD ._. The_DT second_JJ benefit_NN is_VBZ the_DT
        potential_NN to_TO reduce_VB the_DT morbidity_NN due_JJ to_TO febrile_NN
        neutropenia_NN from_IN the_DT high-risk_JJ group_NN by_IN providing_VBG these_DT
        patients_NNS with_IN growth-factor_JJ support_NN before_IN any_DT clinical_JJ
        complications_NNS occur_VBP ._. The_DT third_JJ benefit_NN is_VBZ learning_VBG the_DT
        relationship_NN between_IN high_JJ dose_NN intensity_NN and_CC survival_NN on_IN
        the_DT basis_NN of_IN planned_VBN dose_NN and_CC not_RB actual_JJ delivered_VBN dose_NN ._.
        Implementation_NNP of_IN a_DT risk_NN model_NN can_MD provide_VB better_JJR data_NNS by_IN
        making_VBG the_DT planned_VBN dose_NN closer_JJR to_TO the_DT delivered_VBN dose_NN ,_, and_CC
        the_DT impact_NN of_IN dose_NN can_MD be_VB measured_VBN more_RBR accurately_RB ._.
        Additional_JJ objections_NNS to_TO the_DT model_NN relate_VBP to_TO the_DT
        definition_NN of_IN a_DT neutropenic_JJ complication_NN ,_, in_IN particular_JJ
        dose_NN delays_NNS and_CC dose_NN reductions_NNS ._. Dose_NNP delays_NNS and_CC dose_NN
        reductions_NNS are_VBP events_NNS that_WDT occur_VBP as_IN a_DT result_NN of_IN a_DT clinical_JJ
        decision_NN and_CC not_RB a_DT measured_VBN biological_JJ variable_JJ such_JJ as_IN
        neutropenia_NN based_VBN on_IN ANC_NNP ._. It_PRP could_MD be_VB argued_VBN that_IN these_DT
        decisions_NNS are_VBP not_RB necessarily_RB objective_NN ,_, reflecting_VBG the_DT
        practice_NN pattern_NN of_IN individual_JJ physicians_NNS ,_, and_CC cannot_NN be_VB
        part_NN of_IN the_DT definition_NN of_IN a_DT neutropenic_JJ complication_NN ._. In_IN
        this_DT context_NN it_PRP is_VBZ important_JJ to_TO remember_VB that_IN the_DT purpose_NN
        of_IN the_DT model_NN is_VBZ to_TO identify_VB patients_NNS at_IN risk_NN ._. A_DT physician_NN
        who_WP delays_VBZ or_CC reduces_VBZ the_DT dose_NN of_IN chemotherapy_NN has_VBZ decided_VBN
        that_IN the_DT patient_NN is_VBZ at_IN risk_NN ._. Moreover_RB ,_, once_RB it_PRP is_VBZ decided_VBN
        to_TO reduce_VB or_CC delay_VB the_DT dose_NN ,_, there_EX is_VBZ no_DT way_NN of_IN knowing_VBG the_DT
        rate_NN of_IN neutropenia_NN or_CC febrile_NN neutropenia_NN if_IN the_DT full_JJ dose_NN
        of_IN chemotherapy_NN had_VBD been_VBN delivered_VBN ._. Therefore_RB ,_, including_VBG
        these_DT events_NNS in_IN the_DT definition_NN of_IN a_DT neutropenic_JJ
        complication_NN seems_VBZ justified_JJ ,_, especially_RB if_IN the_DT goal_NN is_VBZ to_TO
        minimize_VB harm_NN to_TO the_DT patients_NNS ._. Admittedly_RB ,_, this_DT methodology_NN
        might_MD result_VB in_IN an_DT overestimation_NN of_IN the_DT number_NN of_IN patients_NNS
        at_IN risk_NN ._.
        Although_IN the_DT model_NN seems_VBZ to_TO be_VB robust_JJ and_CC potentially_RB
        useful_JJ ,_, it_PRP does_VBZ not_RB answer_VB the_DT following_VBG two_CD major_JJ
        questions_NNS ._. If_IN patients_NNS were_VBD stratified_JJ by_IN their_PRP$ risk_NN for_IN
        neutropenic_JJ complications_NNS and_CC provided_VBN with_IN growth-factor_JJ
        support_NN ,_, would_MD the_DT dose_NN intensity_NN delivered_VBD increase_NN and_CC by_IN
        how_WRB much_JJ ?_. Would_MD the_DT rate_NN of_IN neutropenic_JJ complications_NNS
        increase_VBP because_IN of_IN the_DT higher_JJR chemotherapy_NN dose_NN delivered_VBN ?_.
        To_TO answer_VB these_DT questions_NNS decisively_RB ,_, the_DT model_NN needs_VBZ to_TO be_VB
        implemented_VBN prospectively_RB ._.
      
      
        Conclusions_NNP
        The_DT first_JJ step_NN toward_IN the_DT prospective_JJ implementation_NN of_IN
        the_DT model_NN has_VBZ been_VBN performed_VBN and_CC is_VBZ reported_VBN by_IN Rivera_NNP and_CC
        colleagues_NNS [_NN 14_CD ]_NN ._. Additional_JJ prospective_JJ studies_NNS on_IN
        different_JJ regimens_NNS and_CC different_JJ cancer_NN types_NNS would_MD be_VB
        required_VBN to_TO establish_VB the_DT utility_NN and_CC feasibility_NN of_IN this_DT
        model_NN ._. Such_JJ an_DT effort_NN carries_VBZ with_IN it_PRP the_DT promise_NN that_IN
        clinical_JJ criteria_NNS would_MD be_VB used_VBN to_TO deliver_VB appropriate_JJ care_NN
        to_TO patients_NNS with_IN cancer_NN and_CC would_MD maximize_VB the_DT potential_JJ
        benefit_NN from_IN chemotherapy_NN while_IN possibly_RB minimizing_VBG the_DT
        burden_NN on_IN patients_NNS and_CC their_PRP$ caregivers_NNS and_CC families_NNS ._.
      
      
        Competing_VBG interests_NNS
        MHE_NNP is_VBZ an_DT employee_NN of_IN Amgen_NNP Inc_NNP ._. ,_, the_DT manufacturer_NN of_IN
        filgrastim_NN ,_, and_CC owns_VBZ Amgen_NNP stocks_NNS and_CC stock_NN options_NNS ._. MF_NNP is_VBZ
        a_DT consultant_NN to_TO Amgen_NNP Inc_NNP ._. ER_NNP ,_, DF_NNP ,_, and_CC GH_NNP have_VBP no_DT competing_VBG
        interests_NNS ._.
      
      
        Abbreviations_NNP
        ANC_NNP =_SYM absolute_JJ neutrophil_NN count_NN ;_: CAF_NNP =_SYM chemotherapy_NN with_IN
        cyclophosphamide_NN ,_, doxorubicin_NN ,_, fluorouracil_NN ;_: MDACC_NNP =_SYM MD_NNP
        Anderson_NNP Cancer_NNP Center_NNP ._.
      
    
  
